A observational study to evaluate the impact of glucose variability in patients with type 2 diabetes

Korea University Ansan Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新: 2022年6月27日

适应症

试验速览

暂无简介。

•° Patients with type 2 diabetes aged 19 to 80 years
•° Those who will be treated with the following medicines among patients who are receiving or are scheduled to initiate insulin multiple daily injections (MDI)
•Type and product name of insulin
•- Basal insulin: Levemir, Lantus, Tresiba, Toujeo
•- Prandial insulin: NovoRapid, Fiasp, Humalog, Apidra
•- Mixed insulin : Ryzodeg
•° Hypoglycemic agents other than insulin
•- Metformin, Thiazolidinedione (Pioglitazone, Lobeglitazone, Rosiglitazone), Sulfonylurea (Glimepiride, Gliclazide, Glipizide, Glibenclamide), Meglitinide (Repaglinide, Nateglinide, Mitiglinide), DPP4 inhibitor (Sitagliptin, Linagliptin, Gemigliptin, Vildagliptin, Saxagliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin), GLP-1 agonist (Exenatide, Lixisenatide, Liraglutide, Exenatide LAR, Albiglutide, Dulaglutide), SGLT-2 inhibitor (Dapagliflozin, Empagliflozin, Ipragliflozin), a-glucosidase Inhibitor (Acarbose, Voglibose)
•° Fasting C-peptide level measured at the hospital in the past 2 years is 0.4-3.0ng/mL.

•Those who fall under any of the following criteria
•° Insulin pump users
•° Those who have been hospitalized for HHS (hyperglycemia hyperosmolar syndrome), DKA (Diabetic ketoacidosis), acute myocardial infarction, or stroke in the past 3 months
•° Stage 4 or 5 of chronic renal disease (< eGFR 30)
•° Patients with hepatic failure (AST or ALT = 2.5 times the upper normal limit) or symptomatic heart failure with pulmonary oedema
•° Those who are currently receiving anticancer therapy, radiation therapy, and targeted therapy
•° Those who are currently receiving the following medicines that may affect blood glucose
•- Steroid, immunosuppressive agents (cyclosporine, tacrolimus, and sirolimus), nicotinic acid =1500mg/day, systemic isotretinoin, and anti-obesity agents (liraglutide, orlistat, phentermine, phendimetrazine, mazindol)
•- Route of steroid administration: Oral administration and intravenous injection and joint injection are excluded from the study (A nasal spray or inhaler at maintenance dose may be used in this study)
•° Patients with uncontrolled hypertension (SBP =160 mmHg or DBP =100 mmHg)
•° Pregnant or lactating women
•° Those who are determined to be not eligible for this study in the judgment of the investigator

发起方